5 Einträge gefunden

1. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

   1. Reich, K
   2. Gordon, K B
   3. Strober, B
   4. Langley, R G
   5. Miller, M
   6. Yang, Y-W
   7. Shen, Y-K

   2022 - Forschungsinformationssystem des UKE
2. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

   1. Blauvelt, A
   2. Paul, C
   3. van de Kerkhof, P
   4. Warren, R B
   5. Gottlieb, A B
   6. Langley, R G
   7. Brock, F

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

   1. Blauvelt, A
   2. Papp, K
   3. Gottlieb, A
   4. Jarell, A
   5. Reich, K
   6. Maari, C
   7. Gordon, K B

   2020 - Forschungsinformationssystem des UKE
4. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

   1. Reich, K
   2. Blauvelt, A
   3. Armstrong, A
   4. Langley, R G
   5. de Vera, A
   6. Kolbinger, F
   7. Spindeldreher, S

   2019 - Forschungsinformationssystem des UKE
5. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

   1. Lebwohl, M
   2. Langley, R G
   3. Zhu, Y
   4. Zhou, H
   5. Song, M
   6. Shen, Y K
   7. Parnell Lafferty, K

   2019 - Forschungsinformationssystem des UKE